Forget the Cash ISA! I’d buy this FTSE 100 dividend stock to retire on

With its healthy cash flows and defensive market position, this FTSE 100 stock is worth owning in your retirement portfolio, says Rupert Hargreaves.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Warren Buffett, who is widely considered to be the best investor in the world, says that he will only buy stocks when he is sure that the underlying business can continue to produce returns for investors for many years to come.

This means he tends to stick with businesses that have robust competitive advantages or defensive characteristics. 

I think GlaxoSmithKline (LSE: GSK) meets this test. As one of the world’s largest pharmaceutical companies, demand for the group’s products should only increase going forward as the world’s population continues to grow and more money is devoted to healthcare. 

Research and development

Glaxo has spent billions over the past few years reinforcing its position in the market. Moreover, under the stewardship of its relatively new CEO Emma Walmsley, the company has refurbished its research and development efforts.

Rather than spending money on a range of different projects with uncertain outcomes, Glaxo is concentrating its R&D efforts on a few key areas such as vaccines, where it has an established reputation as a reliable supplier. 

These actions to streamline the group’s R&D process, are already having an impact on the bottom line.

Overall sales in the third quarter rose 11% to £9.4bn, beating consensus expectations of about £9bn. Vaccines turnover grew 15% to £2.3bn, primarily driven by growth in sales of Glaxo’s shingles treatment, Shingrix, sales of which jumped 76% in the quarter. 

The company is also on track to start selling a new drug, Dostarlimab in the next few months. Designed to treat advanced or recurrent endometrial cancer, Dostarlimab was one of three drugs Glaxo outlined as being pivotal to its future growth at the beginning of 2019.

The other two were Zejula and Belantamab. They’re both oncology treatments acquired when Glaxo bought Tesaro last year. 

The launch of new respiratory medicines Nucala and Trelegy are also helping drive sales growth at Glaxo’s respiratory business. 

Retirement investment

Glaxo’s performance this year outlines why I think this stock should feature in your retirement portfolio. 

As long as the company continues to invest in its treatment pipeline, new products should continue to power sales growth for many decades to come.

And even if the company only grows in line with the rest of the global healthcare industry, I think the stock has the potential to return around 10% per annum for the next decade or so. 

Indeed, according to research from Deloitte, global healthcare spending is set to increase by around 5% per annum to the middle of the next decade. 

If the company’s earnings grow in line with this projection, I think the stock could return around 9.6% per annum when you add in the 4.6% dividend yield to earnings growth. 

This kind of growth is worth paying a premium for, so I think Glaxo’s current P/E of 14.4 isn’t too demanding and could move higher if the company continues to beat City growth expectations. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »